Isotechnika Pharma Inc IPHAF

Presentation to day at 8 am

[snrkid]

Isotechnika to be represented at ARVO conference with multiple presentations
Thu Apr 24, 8:03 AM

Email Story IM Story Printable View EDMONTON, April 24 /CNW/ - (TSX: ISA.TO) - Isotechnika Inc. announced today that the company's strategic partner, Lux Biosciences, will make multiple presentations on voclosporin (oral formulation, LX211) at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The international meeting is being held from April 27 - May 1 in Fort Lauderdale, Florida.

"We have made major progress in the recruitment of our LUMINATE program and are likely to reach important recruitment milestones in mid-year. We credit our investigators for this timely enrollment, and appreciate their strong interest and high motivation," said Ulrich Grau, Ph.D., Lux Biosciences President and Chief Executive Officer. "The LUMINATE program addresses high medical needs and is potentially an important first: LX211 (oral formulation of voclosporin) is the first steroid sparing agent that is being developed towards approval in sight-threatening, non-infectious uveitis."

Voclosporin will be featured in a poster presentation on April 28. The poster describes the design of the ongoing pivotal trial program in different types of sight-threatening non-infectious uveitis, by clinical investigator J.T. Rosenbaum, M.D. from the Casey Eye Institute-OHSU, Portland, Oregon, on behalf of the international LUMINATE Study Group. Also to be presented by Lux Biosciences and collaborators from the National Eye Institute is a poster on April 30 demonstrating voclosporin's ability to suppress anti-CD3 activated human T cell proliferation and to successfully treat experimental autoimmune uveitis in rats.

Interested parties will be able to access both posters by visiting Isotechnika's corporate website at www.isotechnika .com and accessing the presentations folder in the "For Investors" section.


About Isotechnika